Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the Bioday Registry.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult patients with atopic dermatitis indicated for dupilumab, without current use of oral immunosuppressive treatment .
Locations
Other Locations
Netherlands
University Medical Center Utrecht
RECRUITING
Utrecht
Contact Information
Primary
Roselie Achten, MD
r.e.achten@umcutrecht.nl
0031 88 75 57439
Backup
Marjolein de Bruin-Weller, MD, PhD
m.s.debruin-weller@umcutrecht.nl
Time Frame
Start Date: 2020-02-25
Estimated Completion Date: 2023-12-31
Participants
Target number of participants: 150
Related Therapeutic Areas
Sponsors
Collaborators: Sanofi
Leads: UMC Utrecht